Biliary Tract Cancer
In a phase 3 study presented at the 2018 Gastrointestinal Cancers Symposium, researchers reported on OS outcomes with gemcitabine plus S-1 vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer.
[Clinical Medicine Insights: Oncology] This research examines the role of adjuvant chemotherapy in resectable bile duct cancer treatment.
People who took aspirin on a regular basis were three times less likely to develop the disease.
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer.
Patients with bile duct cancer could be helped by a new class of experimental drug, according to a study.
Nonsignificant improvement in unselected patients, but significant benefit for high-risk patients.
Results from three new studies are consistent with earlier findings that aspirin can reduce cancer risk and, in some cases, metastasis.
Aspirin use lowers the risk of esophageal, gastric, biliary, and breast cancer and reduces distant metastases.
Patients with advanced biliary cancer treated with cisplatin plus gemcitabine experience a significant survival advantage without added toxicity, according to a study published in The New England Journal of Medicine (2010;362(14):1273-1281).
Sign Up for Free e-newsletters
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- Handling Chemotherapy Premedications
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
- Adding Bevacizumab to First-line Chemotherapy Benefits Selects Cases of Ovarian Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|